Moneycontrol
HomeNewsBusinessMarketsAsia shares gain despite Chinese COVID case numbers rising
Trending Topics

Asia shares gain despite Chinese COVID case numbers rising

MSCI's broadest index of Asia-Pacific shares outside Japan was up 0.3%, after U.S. stocks ended the previous session with gains. The index is up 12% so far this month.

November 23, 2022 / 07:43 IST
Story continues below Advertisement

Asian share markets were mostly in positive territory on Wednesday despite rising COVID-19 cases in mainland China leaving investors uncertain over how much the fresh outbreaks could slow the reopening of the world's second-largest economy.

MSCI's broadest index of Asia-Pacific shares outside Japan was up 0.3%, after U.S. stocks ended the previous session with gains. The index is up 12% so far this month.

Story continues below Advertisement

Australian shares were up 0.7%, with most gains coming from mining and resources giants as a result of higher oil prices. Japan's stock market was closed for a national holiday.

New Zealand's central bank raised interest rates by 75 basis points - its largest ever move - on Wednesday to a near 14-year high of 4.25% and flagged more hikes are on the way as it struggles to contain stubbornly high inflation.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show